The Influenza A Virus, H5N1 Subtype Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Influenza A Virus, H5N1 Subtype Infections. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued products.

GlobalData tracks 36 drugs in development for Influenza A Virus, H5N1 Subtype Infections by 32 companies/universities/institutes. The top development phase for Influenza A Virus, H5N1 Subtype Infections is preclinical with 21 drugs in that stage. The Influenza A Virus, H5N1 Subtype Infections pipeline has 27 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Influenza A Virus, H5N1 Subtype Infections pipeline products market are: National Institute of Allergy and Infectious Diseases, Cocrystal Pharma and FluGen.

The key targets in the Influenza A Virus, H5N1 Subtype Infections pipeline products market include Hemagglutinin, Exo Alpha Sialidase (Neuraminidase or Acetylneuraminidase or EC 3.2.1.18), and Polymerase Basic Protein 2 (RNA Directed RNA Polymerase Subunit P3 or PB2).

The key mechanisms of action in the Influenza A Virus, H5N1 Subtype Infections pipeline product include Polymerase Basic Protein 2 (RNA Directed RNA Polymerase Subunit P3 or PB2) Inhibitor with two drugs in Phase I. The Influenza A Virus, H5N1 Subtype Infections pipeline products include five routes of administration with the top ROA being Nasal and ten key molecule types in the Influenza A Virus, H5N1 Subtype Infections pipeline products market including Small Molecule, and Subunit Vaccine.

Influenza A Virus, H5N1 Subtype Infections overview

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain, and diarrhea. Predisposing factors include working with poultry, touching an infected bird, and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

For a complete picture of Influenza A Virus, H5N1 Subtype Infections’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.